Add Yahoo as a preferred source to see more of our stories on Google. As Parkinson’s disease (PD) Awareness Month approaches this April, analysis of the global drug landscape reveals an evolving ...

A new study has revealed how the mutated proteins that are a hallmark of Parkinson’s disease spread and aggregate in the brain. The finding opens the door to developing a way of halting the disease’s ...

Amsterdam, July 22, 2024 – To date Parkinson's disease (PD) is diagnosed clinically and rather late in the course of the disease. There is an urgent need to find an objective, quantifiable biomarker ...

Skin biopsies detected phosphorylated alpha-synuclein in a high proportion of people with Parkinson's disease and other synucleinopathies. Finding a reliable diagnostic biomarker for synucleinopathies ...

“Taken together, our findings highlight both brain region-specific vulnerabilities and global molecular perturbations associated with alpha-synuclein biology and provide insights into early ...

Professor, Aarhus University, Dept. of Biomedicine (West), Director, DANDRITE, Danish Research Institute of Translational Neuroscience, (Nordic EMBL partnership for Molecular Medicine). Co-founder and ...

“These are the first data to link ASC speck assembly, NLRP1 inflammasome activation, and alpha-synuclein aggregation in neurons of Parkinson’s disease patients,” said Stephen C. Glover, ZyVersa’s ...

Inspired by a creature from Greek mythology, researchers have created a ‘two-headed’ drug that prevents the production of the toxic protein linked to Parkinson’s disease before destroying the RNA ...

Their study, "Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson's disease,” was recently published in Nature Communications. The study ...